CD19 MRNA Quantification Improves Rituximab Treatment-to-target Approach: a Proof of Concept Study
Overview
Authors
Affiliations
We compared pre-amplification (PA) RT-PCR blood CD19 mRNA quantification with flow cytometry (FC), to personalize rituximab re-treatment in neuromyelitis optica spectrum disorders (NMOSDs) patients. 47 blood samples from 3 NMOSDs patients were studied. PA-RT-PCR quantified CD19 in all samples, and a positivity threshold was defined, whereas CD19+ B cells were under threshold in 31/47 samples by FC. In all samples where CD19+ B cells were above FC threshold, they resulted above the PA-RT-PCR threshold. CD19 mRNA was above threshold in 8 other samples, resulted negative by FC, and preceded the FC positivity in 7/8 samples by 1-3 months, showing major sensitivity.
Martire S, Valentino P, Marnetto F, Mirabile L, Capobianco M, Bertolotto A Mol Biol Rep. 2022; 49(6):4709-4718.
PMID: 35279776 PMC: 9262796. DOI: 10.1007/s11033-022-07320-5.
Lebrun C, Cohen M, Rosenthal-Allieri M, Bresch S, Benzaken S, Marignier R Neurol Ther. 2018; 7(2):373-383.
PMID: 29881979 PMC: 6283795. DOI: 10.1007/s40120-018-0101-4.
Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study.
Valentino P, Marnetto F, Granieri L, Capobianco M, Bertolotto A Neurol Neuroimmunol Neuroinflamm. 2017; 4(2):e317.
PMID: 28054001 PMC: 5182057. DOI: 10.1212/NXI.0000000000000317.
Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.
Alexopoulos H, Biba A, Dalakas M Neurotherapeutics. 2015; 13(1):20-33.
PMID: 26566961 PMC: 4720683. DOI: 10.1007/s13311-015-0402-6.